122 related articles for article (PubMed ID: 32988633)
1. Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit-Risk Models: The Example of Rotavirus Vaccination in France.
Arlegui H; Nachbaur G; Praet N; Bégaud B; Caro JJ
Clin Ther; 2020 Oct; 42(10):1983-1991.e2. PubMed ID: 32988633
[TBL] [Abstract][Full Text] [Related]
2. Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.
Ledent E; Arlegui H; Buyse H; Basile P; Karkada N; Praet N; Nachbaur G
BioDrugs; 2018 Apr; 32(2):139-152. PubMed ID: 29589230
[TBL] [Abstract][Full Text] [Related]
3. Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.
Ledent E; Lieftucht A; Buyse H; Sugiyama K; Mckenna M; Holl K
Drug Saf; 2016 Mar; 39(3):219-30. PubMed ID: 26748506
[TBL] [Abstract][Full Text] [Related]
4. A benefit-risk analysis of rotavirus vaccination, France, 2015.
Lamrani A; Tubert-Bitter P; Hill C; Escolano S
Euro Surveill; 2017 Dec; 22(50):. PubMed ID: 29258644
[TBL] [Abstract][Full Text] [Related]
5. Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018.
Escolano S; Mueller JE; Tubert-Bitter P
Euro Surveill; 2020 Aug; 25(33):. PubMed ID: 32820718
[TBL] [Abstract][Full Text] [Related]
6. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America.
Desai R; Parashar UD; Lopman B; de Oliveira LH; Clark AD; Sanderson CF; Tate JE; Matus CR; Andrus JK; Patel MM
Clin Infect Dis; 2012 May; 54(10):1397-405. PubMed ID: 22431803
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the potential risks and benefits of infant rotavirus vaccination in England.
Clark A; Jit M; Andrews N; Atchison C; Edmunds WJ; Sanderson C
Vaccine; 2014 Jun; 32(29):3604-10. PubMed ID: 24814524
[TBL] [Abstract][Full Text] [Related]
8. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.
Clark A; Tate J; Parashar U; Jit M; Hasso-Agopsowicz M; Henschke N; Lopman B; Van Zandvoort K; Pecenka C; Fine P; Sanderson C
Lancet Glob Health; 2019 Nov; 7(11):e1541-e1552. PubMed ID: 31607466
[TBL] [Abstract][Full Text] [Related]
9. Potential intussusception risk versus benefits of rotavirus vaccination in the United States.
Desai R; Cortese MM; Meltzer MI; Shankar M; Tate JE; Yen C; Patel MM; Parashar UD
Pediatr Infect Dis J; 2013 Jan; 32(1):1-7. PubMed ID: 22929172
[TBL] [Abstract][Full Text] [Related]
10. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France.
Huet F; Largeron N; Trichard M; Miadi-Fargier H; Jasso-Mosqueda G
Vaccine; 2007 Aug; 25(34):6348-58. PubMed ID: 17629598
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
Standaert B; Parez N; Tehard B; Colin X; Detournay B
Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
[TBL] [Abstract][Full Text] [Related]
12. Effects of rotavirus vaccine on all-cause acute gastroenteritis and rotavirus hospitalizations in Israel: A nationwide analysis.
Muhsen K; Haklai Z; Applbaum Y; Gordon ES; Shteiman A; Glatman-Freedman A; Leshem E
Vaccine; 2020 Feb; 38(10):2406-2415. PubMed ID: 32029322
[TBL] [Abstract][Full Text] [Related]
13. Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.
Bruijning-Verhagen P; van Dongen JAP; Verberk JDM; Pijnacker R; van Gaalen RD; Klinkenberg D; de Melker HE; Mangen MJ
BMC Med; 2018 Sep; 16(1):168. PubMed ID: 30196794
[TBL] [Abstract][Full Text] [Related]
14. Age at First Rotavirus Vaccination and Risk of Intussusception in Infants: A Public Health Modeling Analysis.
Yung CF; Chong CY; Thoon KC
Drug Saf; 2016 Aug; 39(8):745-8. PubMed ID: 27067440
[TBL] [Abstract][Full Text] [Related]
15. Analysis of hospitalizations due to intussusception in Sicily in the pre-rotavirus vaccination era (2003-2012).
Costantino C; Restivo V; Cuccia M; Furnari R; Amodio E; Vitale F
Ital J Pediatr; 2015 Aug; 41():52. PubMed ID: 26232152
[TBL] [Abstract][Full Text] [Related]
16. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis.
Patel MM; Clark AD; Sanderson CF; Tate J; Parashar UD
PLoS Med; 2012; 9(10):e1001330. PubMed ID: 23109915
[TBL] [Abstract][Full Text] [Related]
17. Sustained reduction in rotavirus-coded hospitalizations in children aged <5 years after introduction of self-financed rotavirus vaccines in Japan.
Kobayashi M; Miyazaki M; Ogawa A; Tatsumi M
Hum Vaccin Immunother; 2020; 16(1):132-137. PubMed ID: 31298962
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
[TBL] [Abstract][Full Text] [Related]
19. Impact of rotavirus vaccination on the burden of acute gastroenteritis in Nagoya city, Japan.
Yoshikawa T; Matsuki T; Sato K; Mizuno M; Shibata M; Hasegawa S; Morita M; Iwasa M; Gopala K; Holl K
Vaccine; 2018 Jan; 36(4):527-534. PubMed ID: 29248263
[TBL] [Abstract][Full Text] [Related]
20. Cocontribution of Rotavirus and Pneumococcal Conjugate Vaccines to the Reduction of Pediatric Hospital Visits in Young Children.
Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
J Pediatr; 2017 Mar; 182():253-259.e2. PubMed ID: 27939127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
